๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Bezafibrate for the treatment of primary sclerosing cholangitis

โœ Scribed by Suguru Mizuno; Kenji Hirano; Minoru Tada; Keisuke Yamamoto; Yoko Yashima; Hiroshi Yagioka; Kazumichi Kawakubo; Yukiko Ito; Hirofumi Kogure; Takashi Sasaki; Toshihiko Arizumi; Osamu Togawa; Saburo Matsubara; Yousuke Nakai; Naoki Sasahira; Takeshi Tsujino; Hiroyuki Isayama; Takao Kawabe; Masao Omata; Kazuhiko Koike

Publisher
Springer Japan
Year
2010
Tongue
English
Weight
168 KB
Volume
45
Category
Article
ISSN
0944-1174

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Medical treatment for primary sclerosing
Medical treatment for primary sclerosing cholangitis: Risk versus benefit
โœ Paul Angulo; Keith D. Lindor ๐Ÿ“‚ Article ๐Ÿ“… 2003 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 74 KB

Background: No established medical therapy alters the progressive course of primary sclerosing cholangitis. Objective: To explore the potential usefulness of combined therapy with azathioprine, steroids and ursodeoxycholic acid (UDCA) in primary sclerosing cholangitis. Design: Case series. Setting:

High-dose ursodeoxycholic acid for the t
High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis
โœ Keith D. Lindor; Kris V. Kowdley; Velimir A. C. Luketic; M. Edwyn Harrison; Timo ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 319 KB ๐Ÿ‘ 1 views

Previous controlled trials are inconclusive regarding the efficacy of ursodeoxycholic acid (UDCA) for treating primary sclerosing cholangitis (PSC). One hundred fifty adult patients with PSC were enrolled in a long-term, randomized, double-blind controlled trial of highdose UDCA (28-30 mg/kg/day) ve